Dissertation/Thesis Abstract

In vivo cellular imaging of HER2-overexpressing breast tumor cells through electron paramagnetic resonance (EPR)
by Burks, Scott R., Ph.D., University of Maryland, Baltimore, 2009, 124; 3389000
Abstract (Summary)

Due to recent advances in electron paramagnetic resonance imaging (EPRI) technology, in vivo localization of a single tissue based on unique physiology, has become a real possibility. EPRI could be a powerful imaging modality to define tumor boundaries, detect metastatic lesions, and report tissue-specific physiological information. The Human Epidermal Growth Factor Receptor 2 (HER2) is overexpressed in ∼25-30% of breast tumors. HER2-overexpressing breast tumors exhibit increased proliferation and metastasis, and subsequently, poor clinical prognosis. Presented here, is a novel mechanism for selective delivery of molecular EPRI probes to HER2-overexpressing breast tumor cells. We demonstrate bio-compatibility of EPRI probes we previously developed, and that encapsulation of these probes in liposomes allows cellular accumulation of EPR signal through endocytosis. Encapsulating nitroxides in anti-HER2 immunoliposomes, designed for targeted delivery to cells expressing the HER2 receptor, permits high levels of tissue-specific probe accumulation in breast tumor cells overexpressing HER2 in vitro. We demonstrate that nitroxide-loaded immunoliposomes can be optimized for in vivo applications, and through the use of tumor-bearing animals, provide evidence for the feasibility of targeting HER2-overexpressing tumors in vivo.

Indexing (document details)
Advisor: Kao, Joseph PY
Commitee: Brodie, Angela M., Hamlyn, John M., Martin, Stuart S., Rosen, Gerald M.
School: University of Maryland, Baltimore
Department: Physiology
School Location: United States -- Maryland
Source: DAI-B 71/01, Dissertation Abstracts International
Source Type: DISSERTATION
Subjects: Physiology, Oncology
Keywords: Cancer, HER2, Liposomes, Trastuzumab
Publication Number: 3389000
ISBN: 9781109549232
Copyright © 2019 ProQuest LLC. All rights reserved. Terms and Conditions Privacy Policy Cookie Policy
ProQuest